1 / 1

The Siltuximab Injection pioneers a new era in cancer treatment

At Impomed Healthcare, we are committed to achieving better outcomes in oncology with Siltuximab Injection 79. Our dedication to patient care drives us to offer this innovative treatment, which has shown remarkable efficacy in managing various cancers. With Siltuximab Injection 79, we aim to enhance survival rates, improve quality of life, and provide hope to patients and their families. Trust Impomed Healthcare to deliver cutting-edge solutions in oncology, bringing comfort and progress to those battling cancer.<br> For more information click on this link:- https://www.impomedhealthcare.com/<br><br>

impo
Download Presentation

The Siltuximab Injection pioneers a new era in cancer treatment

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. SILTUXIMAB Home | Cancer | Blood Cancer | SILTUXIMAB SILTUXIMAB Injection Description Composition Dosage Indications SILTUXIMAB 100 / 400 MG INJECTION SYLVANT (siltuximab) is a human-mouse chimeric monoclonal antibody that binds human interleukin-6 (IL-6). SYLVANT is produced by Chinese hamster ovary cells. SYLVANT is supplied as a sterile, white, preservative free, lyophilized powder in single-use vials. Each SYLVANT 100 mg single-use vial contains 100 mg siltuximab, 3.7 mg L-histidine (from L- histidine and L-histidine monohydrochloride monohydrate), 0.8 mg polysorbate 80, and 169 mg sucrose. Each SYLVANT 400 mg single-use vial contains 400 mg siltuximab, 14.9 mg L-histidine (from L-histidine and L-histidine monohydrochloride monohydrate), 3.2 mg polysorbate 80, and 677mg sucrose. Copyright © 2024 ImpoMed Convert web pages and HTML files to PDF in your applications with the Pdfcrowd HTML to PDF API Printed with Pdfcrowd.com

More Related